Wallaceburg hospital fundraising halfway home
The Chatham-Kent Health Alliance Foundation officially launched the Our Hospital, Our Future Wallaceburg Site Redevelopment fundraising campaign recently, with a goal of raising $9 million.
That's the community's portion of the build that will see a re-imagined emergency department and other state-of-the-art services. The project could break ground as early as the summer 2026, CKHA president and CEO Adam Topp told the crowd, with construction on the full-service emergency department to take an estimated two years.
'The next time we get this group together, we'll have our 20,000-square-foot building,' he said, noting he was excited to unveil renderings of the new structure that were on display at the event.
'We have been working really hard to make sure that the building we're going to build represents the community and the wonderful town of Wallaceburg,' he said, noting getting shovels in the ground could take up to two years.
According to Topp, the three-stage capital project is nearing the end of its second phase, with detailed drawings about to be submitted to the province for approval. After that, he said the project will go out to tender followed by construction.
The drive is already halfway to the goal. The Municipality of Chatham-Kent committed $4.5-million towards the redevelopment in 2023 and the Sydenham Ladies Auxiliary is pitching in $100,000.
A number of accomplishments in the site's redevelopment have been made in recent years. This includes the completion of the replacement power plant in 2022, made possible through a $7.3 million investment from the province in 2020.
A new medical daycare facility was opened in 2023.
The province has committed $42 million for the capital project.
CKHA Foundation president and CEO Christine Mitchell echoed Topp on the hospital's importance to Wallaceburg and area.
'This hospital isn't just a building – it's an important part of the history of this community, and today we celebrate that history while also looking towards a bright future for health care here in Wallaceburg and Chatham-Kent,' Mitchell said.
Mitchell called the fundraising launch exciting, noting donors can now see renderings and drawings of the new site – providing a concrete visual for donors.
'We want to continue to engage with the community, to invite them to be with us every step of the way,' she said.
Wallaceburg Coun. Carmen McGregor, who brought greetings on behalf of Chatham-Kent, said she's looking forward to standing on the site 'with a shovel' next year.
In his comments, Lambton-Kent-Middlesex MPP Steve Pinsonneault praised his predecessor Monte McNaughton for taking up the cause to keep Wallaceburg's hospital open.
'Monte tirelessly advocated for this hospital,' Pinsonneault said. 'His deep commitment got us over the threshold of the province getting funding here. I'm looking forward to carrying on Monte's legacy.'
Officials also paid homage to the dogged determination of Save Our Sydenham – the grassroots group formed 16 years ago to stop the proposed closure of the hospital.
S.O.S. founding chairman Jeff Wesley and current chair Conrad Noel also took to the podium. Both men expressed their appreciation to officials and the community for making the hospital's renewal a reality.
'Thank you all for making a difference,' Wesley said, adding the fundraising drive is the final task remaining.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual (under the tongue) formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. 'The FDA approval of Tonmya as a first-line treatment for fibromyalgia represents a landmark advancement for the millions of people in the U.S. suffering from the debilitating pain this condition causes,' said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. 'At Tonix, we recognized the transformative potential of pursuing a new approach with Tonmya for fibromyalgia, a chronic overlapping pain condition (COPC), that has gone without innovation for many years. We are hopeful that effectively treating pain with Tonmya could help improve the lives of people with this chronic syndrome.' 'The chronic pain of fibromyalgia is debilitating to every aspect of a person's life, including causing sleep disturbance and fatigue, all of which can negatively impact someone's ability to carry out their daily activities,' said Sharon Waldrop, a person with lived experience and founder of the Fibromyalgia Association. 'For over 15 years, this community has been underserved and waiting for new treatment options. This approval is a promising step forward and brings renewed hope to millions.' The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. The most common adverse events (incidence ≥2% and at a higher incidence in Tonmya-treated patients compared to placebo-treated patients) included oral hypoesthesia (numbness in the mouth), oral discomfort, abnormal product taste, somnolence (drowsiness), oral paresthesia (tingling, pricking or burning in the mouth), oral pain, fatigue, dry mouth, and aphthous ulcer (canker sore). 'For many years, rheumatologists like myself and other healthcare professionals have had to manage fibromyalgia with limited options that do not adequately meet treatment needs for the majority of patients,' said Philip Mease, M.D., Director of Rheumatology Research at the Providence Swedish Medical Center and Clinical Professor at the University of Washington School of Medicine. 'Tonmya is a novel treatment approach that targets nonrestorative sleep that is characteristic of fibromyalgia and can impact core symptoms, specifically pain.' The latest Phase 3 trial, RESILIENT, was recently published in Pain Medicine with data on primary and secondary endpoints measuring pain, patient's global impression of change, patient-reported symptoms and function, sleep disturbance, and fatigue. 'I know firsthand how the chronic pain of fibromyalgia significantly disrupts my patients' lives.' Andrea L. Chadwick, M.D., MSc, FASA, Anesthesiology, Pain, and Perioperative Medicine at The University of Kansas Health System. 'Treatments that are processed through the liver can result in metabolites that could affect a medicine's efficacy and safety over time. Tonmya is administered sublingually which is designed to reduce pain quickly and durably with a tolerable safety profile.' Tonix thanks the participants and investigators involved in its fibromyalgia clinical trials, and FDA for its commitment to approving new treatments for this condition. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. For more information, visit or download the TONMYA Fact Sheet here. Webcast InformationTonix will host a webcast and conference call on Monday, August 18 at 8:30 AM ET to discuss the approval of Tonmya. The live webcast of the call will be available on the Investors section of Tonix's website: To participate by phone, please register in advance using this link to obtain a local or toll-free phone number and your personal pin. A replay of the webcast will be available for approximately 90 days following the live event. The slides presented during the webcast will be made available on the 'Presentations' page of the 'Investors' section of the Company's website. About FibromyalgiaFibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., approximately 80% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep (waking up tired and unrefreshed), fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Patients with fibromyalgia have double the medical costs compared to the general population in the U.S. About Tonmya™ (cyclobenzaprine HCl sublingual tablets)Tonmya, which was investigated as TNX-102 SL, is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride, which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a tertiary amine tricyclic (TAT) and multifunctional agent with potent binding and antagonist activities at the 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors, Tonmya is now approved as a once-daily bedtime treatment for fibromyalgia in adults. The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10357465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix's proprietary composition. These patents are expected to provide Tonmya with U.S. market exclusivity until 2034. Pending patent applications related to method of use could extend exclusivity until 2044. About the Phase 3 Clinical Trials: RELIEF and RESILIENTThe RELIEF and RESILIENT studies were double-blind, randomized, placebo-controlled trials designed to evaluate the efficacy and safety of Tonmya™ (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia. RELIEF and RESILIENT were two-arm trials that enrolled 503 and 457 adults with fibromyalgia across 40 and 33 United States sites, respectively. In both trials, the first two weeks of treatment consisted of a run-in period in which participants started on Tonmya 2.8 mg (1 tablet) or placebo. Thereafter, all participants increased their dose to Tonmya 5.6 mg (2 x 2.8 mg tablets) or two placebo tablets for the remaining 12 weeks. The primary endpoint across both trials was the daily diary pain intensity score change (Tonmya 5.6 mg vs. placebo) from baseline to Week 14 (using the weekly averages of the daily numerical rating scale scores). Additional details on RELIEF (NCT04172831) and RESILIENT (NCT05273749) are available on RALLY was a replicate Phase 3 trial to RELIEF and RESILIENT that demonstrated greater but non-significant treatment effect with Tonmya compared to placebo and demonstrated consistent safety. Results of this trial may not have been generalizable due to the presence of factors outside the conduct of the study. Additional details are available on (NCT04508621). Tonix Pharmaceuticals Holding is a fully-integrated biotechnology company. Tonix's development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology and infectious diseases. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, Inc., our wholly-owned commercial subsidiary, markets treatments for fibromyalgia and acute migraine. This press release and further information about Tonix can be found at Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the 'SEC') on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contacts Jessica Morris Tonix Pharmaceuticals (862) 799-8599 Brian Korb astr partners (917) 653-5122 Media Contact Meagen HagansWeber Shandwick(757)358-2033MHagans@ INDICATIONTONMYA is indicated for the treatment of fibromyalgia in adults. CONTRAINDICATIONSTONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs. During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. In patients with hyperthyroidism. WARNINGS AND PRECAUTIONS Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy. Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases. Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures. Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs. CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur. ADVERSE REACTIONSThe most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer. DRUG INTERACTIONS MAO inhibitors: Life-threatening interactions may occur. Other serotonergic drugs: Serotonin syndrome has been reported. CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced. Tramadol: Seizure risk may be enhanced. Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED). Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition. Pediatric use: The safety and effectiveness of TONMYA have not been established. Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions. Please see additional safety information in the full Prescribing Information. To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-08-2025
- Yahoo
Newly qualified doctors face ‘recurring cycle of debt', BMA warns
Newly qualified doctors are driving Ubers and working in bars to make ends meet as they face a 'recurring cycle of debt', the British Medical Association (BMA) has said. Students from poorer backgrounds are hit hardest, the union claims, as it calls on the Government to address the funding gap and make a career in medicine accessible to people from as many backgrounds as possible. Students in their final undergraduate year, along with those in the later years of a post-graduate medical degree, get a reduced student loan alongside an NHS bursary. This leads to a £3,674 drop in funding on average, according to the BMA. Sophie Mitchell, deputy co-chair (finance) of the BMA's medical students' committee, told the PA news agency: 'A lot of people are using these loans in previous years to either pay their rent and to live off. 'Losing out on a significant portion of that is meaning that students are struggling. 'We've got people maxing out overdrafts, we've got people maxing out credit cards. 'We've got people going into very significant debt just to actually finish this degree.' The average medical student faces 12 months of this reduced funding. However, some post-graduate students, along with those on six-year degree programmes, face up to three years, Ms Mitchell said. Some are them are also faced with relocation expenses ahead of starting their first job in the NHS. 'The issue with that is most academic years or final years start in around the middle of August,' Ms Mitchell said. 'You are then having this reduced rate of funding until you then get paid at the end of August the following year. 'I know that a lot of my colleagues have had to get loans to pay their rent, or they've had to get credit agreements so that they can pay their rent. 'Also then having to relocate to a new place where you're getting this reduced rate of funding has been a struggle for a lot of people. 'A lot of my friends were already graduating, maxing out their overdrafts, and then they've had to get overdraft extensions to help them live until they get paid at the end of August. 'It's creating this recurrent cycle of debt that people are really struggling to get out of until that first paycheck.' Ms Mitchell said she knows of new graduates stewarding football matches or taking zero hours bar work to get by. She added: 'We have people working behind bars. 'We have people stewarding. 'One of my friends is actually working for Uber at the moment, because it was the only work that she could get that meant that she could get some employment in the area that she's in.' Ms Mitchell is heading the BMA's Fix Our Finance campaign alongside co-chair Henry Budden. 'Quite a common thing that we've heard about the campaign is 'every student gets a job, why are you guys complaining so much?',' she told PA. 'But I think what people maybe aren't so aware of is actually how intense our course is. 'You're training for that role that you're about to start. 'You're in hospital Monday to Friday, nine to five. 'Some universities make their students do night shifts. 'Some universities make their students also do weekends on top of this. 'And then on top of that placement, where you're learning to be a doctor, you're also having to revise for your exams.' The BMA is calling on the Government to ensure medical students receive full student finance maintenance for the entirety of their course. The union claims this would cost the Treasury £24 million and just 0.12% of Student Finance England annual lending. Ms Mitchell and Mr Budden warned the 'situation isn't sustainable' and 'does nothing to help those from poorer backgrounds or improve participation in medicine'. 'Medicine is longer than many other degrees for good reason; because we want to ensure doctors working in the NHS have the best possible training,' they added. 'It is only right then that they should receive the appropriate funding to see them through the entirety of their course.' A Government spokesperson said: 'NHS bursary grants were uplifted from last September for the first time since 2015 and will increase again by forecast inflation this year, but we know there is more to do to support future NHS doctors. 'The 10-Year Health Plan explicitly acknowledges that the cost of studying medicine is a barrier for working-class students. 'We are determined to break down these barriers and ensure the NHS workforce reflects the communities it serves, which is why we're exploring options to improve financial support to students from the lowest socio-economic background so that they are able to thrive at medical school.'
Los Angeles Times
08-08-2025
- Los Angeles Times
Polyglutamic Acid vs. Hyaluronic Acid: Which is More Hydrating?
LA Times Studios may earn commission from purchases made through our links. Both hyaluronic acid (HA) and polyglutamic acid (PGA) are superstars for hydration, but they work in distinctly different ways. And together, they're a game-changing duo for late summer and fall skin. Hyaluronic acid is famous for holding up to 1,000 times its weight in water, delivering instant plumpness but sometimes leaving skin feeling sticky or prone to moisture loss, especially as the air gets drier. Polyglutamic acid ups the ante. Research says it can hold up to four times more moisture than HA, but that it works differently. It forms an invisible, breathable film on the skin's surface that locks in hydration and strengthens the barrier against environmental stress, even slowing the enzymes that break down HA. Where HA draws moisture into the skin, PGA helps keep it there. Dermatologists now recommend layering both: HA as the inner hydrator, PGA as the outer seal. This double-hit routine not only boosts dewiness but also helps calm sensitivity, support skin resilience, and keep your glow going strong through seasonal shifts. Still loyal to that trusty hyaluronic acid serum every time your skin cries out for moisture? You're in good company. This molecule has dominated the hydration game for a decade, becoming the poster child for 'dewy' skin among beauty insiders and dermatologists alike. But new sets of hydrators are quietly changing the rules. Now, it's all about ingredients that flex with your life, protect your barrier, and make your glow more resilient than ever. As humidity drops and temperatures fluctuate, your skin's barrier gets stressed, making traditional hydration strategies less effective. 'Skin hydration isn't just about adding water, it's about holding onto it,' explains board-certified dermatologist Dr. Hope Mitchell. Polyglutamic acid is a next-gen hydrator with real staying power. Think of it as a lightweight, breathable shield that locks in moisture right at the surface, so your skin doesn't lose it to the dry, swirling fall air. 'Polyglutamic acid is a larger molecule,' Dr. Mitchell explains. 'It sits on top of the skin, forming a breathable film that locks in water while still hydrating.' PGA forms a protective film, reducing transepidermal water loss and helping skin stay plump and resilient, even as the seasons flip. Translation? More bounce and fewer fine lines. Snow mushroom (aka tremella), on the other hand, works differently and acts like tiny water magnets…drawing hydration into the skin. K-beauty devotees have nicknamed it 'nature's hyaluronic acid,' but new research shows its unique polysaccharides may keep skin hydrated even longer than synthetic HA, especially when your skin barrier is stressed Mitchell explains that snow mushroom can be exceptionally soothing when the skin transitions from humid heat to drier fall air. It's tempting to ditch heavy creams as the weather cools, but here's the fall update: lighter layers still rule, but with a focus on barrier support. Swap your thickest balms for hydrating essences and water-light serums that feature polyglutamic acid and tremella. Lock everything in with a gel-cream packed with ceramides — this minimalist layering helps sensitive skin handle both humidity and dryness. This is the moment for skin barrier repair. When your face feels tight, itchy, or just out of sorts as the air shifts, the real culprit is usually a compromised barrier. Experts say that proper hydration is essential for supporting skin structure and delivering nutrients to skin cells which is why combining hydrators like PGA and tremella with barrier boosters like niacinamide is key for smoother, calmer skin through seasonal changes. The changing season isn't just about moisture but about gentle actives like bakuchiol and azelaic acid to help you keep your glow without the risk of irritation. Bakuchiol evens out tone and smooths lines, while azelaic acid tackles redness and brightens stubborn spots. The new science of skin hydration is that you now get to pick ingredients that align with your barrier and calendar. Click here to learn more about No7 Beauty
